Suberoylanilide Hydroxamic Acid in Advanced Solid Tumors

This study has been completed.

Study NCT00106626 Information provided by Merck

First Received on March 28, 2005. Last Updated on March 16, 2009 History of Changes

Results First Received: November 25, 2008

Study Type:	Interventional
Study Design:	Allocation: Non-Randomized; Endpoint Classification: Safety Study; Intervention Model: Single Group Assignment; Masking: Open Label; Primary Purpose: Treatment
Condition:	Advanced Cancer
Intervention:	Drug: vorinostat (Suberoylanilide Hydroxamic Acid [SAHA]) in combination with Pemetrexed and Cisplatin

Participant Flow

Hide Participant Flow

Recruitment Details

Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
First Patient In = 29-Aug-05. Last Patient Last Visit = 03-Dec-07. Multicenter (4 Outpatient Clinics) in US.

Pre-Assignment Details

Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
Post-group assignment information: For all cohorts doses were administered in repeated 21-day cycles. Determination of the Maximum Tolerated Dose (MTD), by using dose-escalating design and measured by Dose Limiting Toxicity (DLT) is a standard procedure in the development of chemotherapeutic combinations.

Significant events and approaches for the overall study following participant enrollment, but prior to group assignment

Post-group assignment information: For all cohorts doses were administered in repeated 21-day cycles.

Determination of the Maximum Tolerated Dose (MTD), by using dose-escalating design and measured by Dose Limiting Toxicity (DLT) is a standard procedure in the development of chemotherapeutic combinations.

Reporting Groups

	Description
Cohort A - Vorinostat BID + Pemetrexed + Cisplatin	Dose level A.1 - Vorinostat 200 mg twice daily (BID) for 14 days out of 3 weeks + Pemetrexed + Cisplatin Dose level A.2 - Vorinostat 300 mg twice daily (BID) for 3 consecutive days out of 7 days in first week, two weeks off + Pemetrexed + Cisplatin
Cohort B - Vorinostat QD + Pemetrexed + Cisplatin	Dose level B.1 - Vorinostat 300 mg once daily (QD) for 7 days + Pemetrexed + Cisplatin Dose level B.2 - Vorinostat 400 mg once daily (QD) for 7 days + Pemetrexed + Cisplatin
Cohort C - Vorinostat BID + Pemetrexed	Dose level C.1 - Vorinostat 300 mg twice daily (BID) for 3 consecutive days out of 7 days in first week, two weeks off + Pemetrexed Dose level C.2 - Vorinostat 300 mg twice daily (BID) for 3 consecutive days out of 7 days in first two weeks, one week off + Pemetrexed Dose level C.3 - Vorinostat 300 mg twice daily (BID) for 3 consecutive days out of 7 days repeated weekly + Pemetrexed
Cohort D - Vorinostat QD + Pemetrexed	Dose level D.1 - Vorinostat 300 mg once daily (QD) for 7 days + Pemetrexed Dose level D.2 - Vorinostat 400 mg once daily (QD) for 7 days + Pemetrexed

Participant Flow: Overall Study

	Cohort A - Vorinostat BID + Pemetrexed + Cisplatin	Cohort B - Vorinostat QD + Pemetrexed + Cisplatin	Cohort C - Vorinostat BID + Pemetrexed	Cohort D - Vorinostat QD + Pemetrexed
STARTED	13	9	14	16
COMPLETED	3	3	2	3
NOT COMPLETED	10	6	12	13
Adverse Event	5	4	3	3
Progressive Disease	4	1	9	10
Received radiation on new therapy	1	0	0	0
> 14 day delay in therapy start	0	1	0	0

Baseline Characteristics

Hide Baseline Characteristics

Reporting Groups

	Description
Cohort A - Vorinostat BID + Pemetrexed + Cisplatin	Dose level A.1 - Vorinostat 200 mg twice daily (BID) for 14 days out of 3 weeks + Pemetrexed + Cisplatin Dose level A.2 - Vorinostat 300 mg twice daily (BID) for 3 consecutive days out of 7 days in first week, two weeks off + Pemetrexed + Cisplatin
Cohort B - Vorinostat QD + Pemetrexed + Cisplatin	Dose level B.1 - Vorinostat 300 mg once daily (QD) for 7 days + Pemetrexed + Cisplatin Dose level B.2 - Vorinostat 400 mg once daily (QD) for 7 days + Pemetrexed + Cisplatin
Cohort C - Vorinostat BID + Pemetrexed	Dose level C.1 - Vorinostat 300 mg twice daily (BID) for 3 consecutive days out of 7 days in first week, two weeks off + Pemetrexed Dose level C.2 - Vorinostat 300 mg twice daily (BID) for 3 consecutive days out of 7 days in first two weeks, one week off + Pemetrexed Dose level C.3 - Vorinostat 300 mg twice daily (BID) for 3 consecutive days out of 7 days repeated weekly + Pemetrexed
Cohort D - Vorinostat QD + Pemetrexed	Dose level D.1 - Vorinostat 300 mg once daily (QD) for 7 days + Pemetrexed Dose level D.2 - Vorinostat 400 mg once daily (QD) for 7 days + Pemetrexed

Baseline Measures

	Cohort A - Vorinostat BID + Pemetrexed + Cisplatin	Cohort B - Vorinostat QD + Pemetrexed + Cisplatin	Cohort C - Vorinostat BID + Pemetrexed	Cohort D - Vorinostat QD + Pemetrexed	Total
Number of Participants [units: participants]	13	9	14	16	52
Age [units: years] Mean ( Full Range )	60.52 ( 35 to 81 )	58.23 ( 31 to 74 )	60.09 ( 41 to 78 )	63.63 ( 39 to 81 )	61 ( 31 to 81 )
Gender [units: participants]
Female	4	5	7	8	24
Male	9	4	7	8	28
Race/Ethnicity [units: participants]
Asian	0	0	0	1	1
Black	0	2	0	1	3
European	0	1	0	0	1
Hispanic American	1	0	0	2	3
White	12	6	14	12	44

Outcome Measures

Show All Outcome Measures

1. Primary:

Maximum Tolerated Dose (MTD) Status as Determined by Number of Participants With Dose Limiting Toxicity (DLT) at Each Dose Level [ Time Frame: Cycle 1 (21 days) ]

Show Outcome Measure 1

2. Secondary:

Safety and Tolerability as Measured by the Number of Participants With Disease Progression [ Time Frame: Any time during 8 cycle treatment period through 30 days after. ]

Show Outcome Measure 2

Serious Adverse Events

Show Serious Adverse Events

Other Adverse Events

Show Other Adverse Events

More Information

Hide More Information

Certain Agreements:

All Principal Investigators ARE employed by the organization sponsoring the study.

Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.

Results Point of Contact:

Name/Title: Senior Vice President, Clinical and Quantitative Sciences
Organization: Merck & Co., Inc.
phone: 1-800-672-6372

No publications provided

Responsible Party:	Executive Vice President, Clinical and Quantitative Sciences, Merck & Co., Inc.
ClinicalTrials.gov Identifier:	NCT00106626 History of Changes
Other Study ID Numbers:	2005_006, MK0683-012
Study First Received:	March 28, 2005
Results First Received:	November 25, 2008
Last Updated:	March 16, 2009
Health Authority:	United States: Food and Drug Administration